Effect of adjuvanting RBD-dimer-based subunit COVID-19 vaccines with Sepivac SWE™.
Adjuvant
COVID-19 vaccine
Protein subunit vaccine
SARS-CoV-2 vaccine
SWE
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
24 04 2023
24 04 2023
Historique:
received:
04
10
2022
revised:
12
03
2023
accepted:
16
03
2023
medline:
19
4
2023
pubmed:
27
3
2023
entrez:
26
3
2023
Statut:
ppublish
Résumé
Protein subunit vaccines have been widely used to combat infectious diseases, including the current COVID-19 pandemic. Adjuvants play the key role in shaping the quality and magnitude of the immune response to protein and inactivated vaccines. We previously developed a protein subunit COVID-19 vaccine, termed ZF2001, based on an aluminium hydroxide-adjuvanted tandem-repeat dimeric receptor-binding domain (RBD) of the viral spike (S) protein. Here, we described the use of a squalene-based oil-in-water adjuvant, Sepivac SWE™ (abbreviated to SWE), to further improve the immunogenicity of this RBD-dimer-based subunit vaccines. Compared with ZF2001, SWE adjuvant enhanced the antibody and CD4
Identifiants
pubmed: 36967286
pii: S0264-410X(23)00319-5
doi: 10.1016/j.vaccine.2023.03.035
pmc: PMC10028357
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Adjuvants, Vaccine
0
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2793-2803Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Y.A., K.X., L.D., and G.F.G. are listed in the patent as the inventors of the RBD-dimer as a betacoronavirus vaccine. The patent has been licensed to Anhui Zhifei Longcom for protein subunit COVID-19 vaccine development. All other authors declare no competing interests.